Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep712 | Pituitary and Neuroendocrinology | ECE2023

Thyroid fine needle aspiration for the diagnosis of Langerhans Cell Histiocytosis of the suprasellar region

Sciotto-Canel Lucie , Lopes Stephanie Andrade , Caironi Verdiana , Saiji Essia , Vargas Maria-Isabelle , Jornayvaz Francois R , Momjian Shahan , Stalder Gregoire , Leboulleux Sophie , Mavromati Maria

A 25-year old woman with Hashimoto thyroiditis was referred to the endocrinology department for investigation of a 40 kilogram weight gain, polyuria, polydipsia and secondary amenorrhea. Hormonal work-up showed diabetes insipidus, central hypogonadism, secondary adrenal insufficiency, central hypothyroidism and slight hyperprolactinemia. Pituitary magnetic resonance imaging (MRI) revealed a 15 mm hypothalamic tumor expanding to the infundibulum, associated with pituitary stalk...

ea0081oc1.3 | Oral Communications 1: Diabetes, Obesity, Metabolism and Nutrition 1 | ECE2022

Canakinumabin patients with COVID-19 and type 2 diabetes (CanCovDia) – a multicentric, randomised, double-blind, placebo-controlled phase 3 trial

Hepprich Matthias , Mudry Jonathan , Gregoriano Claudia , Jornayvaz Francois R , Carballo Sebastian , Wojtusciszyn Anne , Bart Pierre-Alexandre , Chiche Jean-Daniel , Fischli Stefan , Baumgartner Thomas , Cavelti-Weder Claudia , Beuschlein Felix , Braun Dominque L , Gunthard Huldrych F , West Emily , Conen Anna , Isenring Egon , Bucklar Gabriela , Aubry Yoann , Dey Ludovic , Muller Beat , Schutz Philipp , Cattaneo Marco , Hunziker Patrick , Donath Marc Y

Background: Patients with type 2 diabetes and overweight have a chronic activation of the innate immune system possibly explaining the increased risk of a hyperinflammatory response and severe COVID-19. We aimed to test whether blockade of interleukin-1β(IL-1β) using canakinumab improves clinical outcome.Methods: CanCovDia was a multicenter, randomised, double-blind, placebo-controlled trial to assess the efficacy of canakinumab plus standard-o...